Long-term incidence of death due to thromboembolic disease among patients with unprovoked pulmonary embolism

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose of review: To summarize recent studies that have quantified the incidence of death due to late thromboembolic disease among patients initially diagnosed with acute unprovoked pulmonary embolism. These findings will aid clinicians who must weigh the risk versus the benefits of long-term anticoagulant therapy. RECENT FINDINGS: The incidence of death due to fatal acute recurrent pulmonary embolism following 3-6 months of anticoagulant therapy is approximately 0.2-0.4% per year, depending in part on the presence or absence of chronic comorbidity. In addition, up to 1-3% of all patients with pulmonary embolism are diagnosed with chronic thromboembolic pulmonary hypertension within 3 years of the index event. Patients with acute pulmonary embolism who develop acute pulmonary hypertension greater than 50 mmHg that does not resolve in the first few weeks are at highest risk for progression, particularly if the event is recurrent pulmonary embolism. SUMMARY: The incidence of death due to recurrent pulmonary embolism or significantly debilitating or fatal thromboembolic pulmonary hypertension in the first 3 years after anticoagulant treatment is discontinued is approximately 1-3%. In patients in whom the risk of fatal or disabling hemorrhage is lower, the benefits of chronic anticoagulation may outweigh the risks.

Original languageEnglish (US)
Pages (from-to)418-424
Number of pages7
JournalCurrent Opinion in Pulmonary Medicine
Volume15
Issue number5
DOIs
StatePublished - Sep 2009

Fingerprint

Pulmonary Embolism
Incidence
Pulmonary Hypertension
Anticoagulants
Comorbidity
Therapeutics
Hemorrhage

Keywords

  • Chronic thromboembolic pulmonary hypertension
  • Death
  • Epidemiology
  • Pulmonary embolism
  • Venous thromboembolism

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

@article{8cf853a85a9f4a9488ed15c6b3553f5f,
title = "Long-term incidence of death due to thromboembolic disease among patients with unprovoked pulmonary embolism",
abstract = "Purpose of review: To summarize recent studies that have quantified the incidence of death due to late thromboembolic disease among patients initially diagnosed with acute unprovoked pulmonary embolism. These findings will aid clinicians who must weigh the risk versus the benefits of long-term anticoagulant therapy. RECENT FINDINGS: The incidence of death due to fatal acute recurrent pulmonary embolism following 3-6 months of anticoagulant therapy is approximately 0.2-0.4{\%} per year, depending in part on the presence or absence of chronic comorbidity. In addition, up to 1-3{\%} of all patients with pulmonary embolism are diagnosed with chronic thromboembolic pulmonary hypertension within 3 years of the index event. Patients with acute pulmonary embolism who develop acute pulmonary hypertension greater than 50 mmHg that does not resolve in the first few weeks are at highest risk for progression, particularly if the event is recurrent pulmonary embolism. SUMMARY: The incidence of death due to recurrent pulmonary embolism or significantly debilitating or fatal thromboembolic pulmonary hypertension in the first 3 years after anticoagulant treatment is discontinued is approximately 1-3{\%}. In patients in whom the risk of fatal or disabling hemorrhage is lower, the benefits of chronic anticoagulation may outweigh the risks.",
keywords = "Chronic thromboembolic pulmonary hypertension, Death, Epidemiology, Pulmonary embolism, Venous thromboembolism",
author = "White, {Richard H} and Susan Murin",
year = "2009",
month = "9",
doi = "10.1097/MCP.0b013e32832d044a",
language = "English (US)",
volume = "15",
pages = "418--424",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Long-term incidence of death due to thromboembolic disease among patients with unprovoked pulmonary embolism

AU - White, Richard H

AU - Murin, Susan

PY - 2009/9

Y1 - 2009/9

N2 - Purpose of review: To summarize recent studies that have quantified the incidence of death due to late thromboembolic disease among patients initially diagnosed with acute unprovoked pulmonary embolism. These findings will aid clinicians who must weigh the risk versus the benefits of long-term anticoagulant therapy. RECENT FINDINGS: The incidence of death due to fatal acute recurrent pulmonary embolism following 3-6 months of anticoagulant therapy is approximately 0.2-0.4% per year, depending in part on the presence or absence of chronic comorbidity. In addition, up to 1-3% of all patients with pulmonary embolism are diagnosed with chronic thromboembolic pulmonary hypertension within 3 years of the index event. Patients with acute pulmonary embolism who develop acute pulmonary hypertension greater than 50 mmHg that does not resolve in the first few weeks are at highest risk for progression, particularly if the event is recurrent pulmonary embolism. SUMMARY: The incidence of death due to recurrent pulmonary embolism or significantly debilitating or fatal thromboembolic pulmonary hypertension in the first 3 years after anticoagulant treatment is discontinued is approximately 1-3%. In patients in whom the risk of fatal or disabling hemorrhage is lower, the benefits of chronic anticoagulation may outweigh the risks.

AB - Purpose of review: To summarize recent studies that have quantified the incidence of death due to late thromboembolic disease among patients initially diagnosed with acute unprovoked pulmonary embolism. These findings will aid clinicians who must weigh the risk versus the benefits of long-term anticoagulant therapy. RECENT FINDINGS: The incidence of death due to fatal acute recurrent pulmonary embolism following 3-6 months of anticoagulant therapy is approximately 0.2-0.4% per year, depending in part on the presence or absence of chronic comorbidity. In addition, up to 1-3% of all patients with pulmonary embolism are diagnosed with chronic thromboembolic pulmonary hypertension within 3 years of the index event. Patients with acute pulmonary embolism who develop acute pulmonary hypertension greater than 50 mmHg that does not resolve in the first few weeks are at highest risk for progression, particularly if the event is recurrent pulmonary embolism. SUMMARY: The incidence of death due to recurrent pulmonary embolism or significantly debilitating or fatal thromboembolic pulmonary hypertension in the first 3 years after anticoagulant treatment is discontinued is approximately 1-3%. In patients in whom the risk of fatal or disabling hemorrhage is lower, the benefits of chronic anticoagulation may outweigh the risks.

KW - Chronic thromboembolic pulmonary hypertension

KW - Death

KW - Epidemiology

KW - Pulmonary embolism

KW - Venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=68949192571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949192571&partnerID=8YFLogxK

U2 - 10.1097/MCP.0b013e32832d044a

DO - 10.1097/MCP.0b013e32832d044a

M3 - Article

C2 - 19458530

AN - SCOPUS:68949192571

VL - 15

SP - 418

EP - 424

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 5

ER -